Evolving therapies for lower-risk myelodysplastic syndromes
|
Apr 2020
|
Annals of Hematology
|
myelodysplastic syndromes (MDS)
|
Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry
|
May 2020
|
Annals of Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion
|
Oct 2019
|
Annals of Hematology
|
myelodysplastic syndromes (MDS)
|
Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry
|
Jul 2020
|
Annals of Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes
|
Oct 2020
|
Annals of internal medicine
|
myelodysplastic syndromes (MDS)
|
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|
Nov 2020
|
Annals of Oncology: Official Journal of the European Society for Medical Oncology
|
myelodysplastic syndromes (MDS)
|
Molecular Pathophysiology of Myelodysplastic Syndromes.
|
Aug 2012
|
Annu Rev Pathol
|
myelodysplastic syndromes (MDS)
|
Antibodies in the treatment of aplastic anemia.
|
Feb 2012
|
Arch Immunol Ther Exp
|
aplastic anemia
|
Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes
|
Jan 2017
|
Asia Pac J Clin Oncol
|
myelodysplastic syndromes (MDS)
|
Revisiting use of growth factors in myelodysplastic syndromes
|
May 2012
|
Asian Pac J Cancer Prev
|
myelodysplastic syndromes (MDS)
|